Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587272 · ClinicalTrials.gov registry record · Phase 2
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by Robert Nickel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 7
- Study locations
NCT03587272: Recruiting Phase 2 study of Sickle Cell Disease, sponsored by Robert Nickel.
NCT03587272 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by Robert Nickel. The registered enrollment target is 100 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587272, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Robert Nickel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
Primary Outcome
Acute grade II-IV GVHD
Conditions Studied
Interventions
- DRUG Alemtuzumab, low dose total body irradiation, Sirolimus
Study Locations (7)
District of Columbia
- Children's National Health System - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
New York
- Columbia University - New York
North Carolina
- Levine Children's Hospital - Charlotte
Ohio
- Nationwide Children's Hospital - Columbus
Alberta
- Alberta Children's Hospital - Calgary
Ontario
- The Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2030-11 |
| Phase | Phase 2 |
What NCT03587272 shows while recruiting
NCT03587272 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Alemtuzumab, low dose total body irradiation, Sirolimus is the first listed.
NCT03587272 lists 7 locations in 7 states (District of Columbia, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT03587272 about?
NCT03587272 is a clinical study titled "Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease". This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate f...
What is the current status of trial NCT03587272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-04-17. Estimated completion is 2030-11.
What conditions does trial NCT03587272 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT03587272?
The interventions under investigation include: Alemtuzumab, low dose total body irradiation, Sirolimus (DRUG).
Who is sponsoring clinical trial NCT03587272?
This trial is sponsored by Robert Nickel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587272 being conducted?
This trial has 7 study locations across District of Columbia, Illinois, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03587272's enrollment target sits among peer trials
100 60th of 213 higher than 150 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI